Principal Investigator
Macarena De La Fuente
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221037
Clinical Trial Summary
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Neurological Cancer
Contact Information
Phone Number
305-243-2647